Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I/II, Randomized, Open-label Platform Study Utilizing a Master Protocol to Study Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Anti-Cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) - DREAMM 5

Next Previous
Trial Profile

A Phase I/II, Randomized, Open-label Platform Study Utilizing a Master Protocol to Study Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Anti-Cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) - DREAMM 5

Status: Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 15 Sep 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Belantamab mafodotin (Primary) ; Dexamethasone (Primary) ; Dostarlimab (Primary) ; Feladilimab (Primary) ; GSK 3174998 (Primary) ; Isatuximab (Primary) ; Lenalidomide (Primary) ; Nirogacestat (Primary) ; Pomalidomide (Primary)
  • Indications Multiple myeloma
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Acronyms DREAMM5
  • Sponsors GlaxoSmithKline Research & Development; GSK

Most Recent Events

  • 06 Nov 2025 Actual primary completion date changed from 14 Feb 2024 to 17 Apr 2025.
  • 21 Jan 2025 New trial record
  • 17 Jun 2022 Results (n=10; data cut-off Nov 15, 2021) assessing efficacy and safety (synergistic effects) of low dose belantamab mafodotin in combination with nirogacestat in patients with relapsed/refractory multiple myeloma, presented at the 27th Congress of the European Haematology Association.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top